Europe preventive vaccines market accounted for $10.64 billion in 2020 and will grow by 10.72% annually over 2020-2026 owing to the increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 61 tables and 52 figures, this 140-page report “Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire Europe preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.
Based on Vaccine Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases
Based on Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
Based on Patient, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter’s Fiver Forces Analysis 35
3 Segmentation of Europe Market by Vaccine Type 39
3.1 Market Overview by Vaccine Type 39
3.2 Live/Attenuated Vaccines 41
3.3 Inactivated Vaccines 42
3.4 Subunit Vaccines 43
3.5 Toxoid Vaccines 44
3.6 Conjugate Vaccines 45
3.7 Recombinant Vector Vaccines 46
3.8 Other Vaccines 47
4 Segmentation of Europe Market by Disease 48
4.1 Market Overview by Disease 48
4.2 Vaccines for Pneumococcal Disease 50
4.3 Vaccines for Poliovirus 51
4.4 Vaccines for Hepatitis 52
4.5 Vaccines for Influenza 53
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 54
4.7 Vaccines for Varicella 55
4.8 Vaccines for Human Papilloma Virus 56
4.9 Vaccines for COVID-19 57
4.10 Vaccines for Other Diseases 60
5 Segmentation of Europe Market by Administration 61
5.1 Market Overview by Administration 61
5.2 Intramuscular Route 63
5.3 Subcutaneous Route 64
5.4 Oral Route 65
5.5 Intravenous Injection 66
5.6 Other Administration Routes 67
6 Segmentation of Europe Market by Patient 68
6.1 Market Overview by Patient 68
6.2 Pediatric Vaccines 70
6.3 Adult Vaccines 72
7 European Market 2020-2026 by Country 74
7.1 Overview of European Market 74
7.2 UK 77
7.3 France 80
7.4 Germany 83
7.5 Spain 86
7.6 Italy 89
7.7 Russia 92
7.8 Rest of European Market 95
8 Competitive Landscape 97
8.1 Overview of Key Vendors 97
8.2 New Product Launch, Partnership, Investment, and M&A 100
…continued
CONTACT DETAILS :
+44 203 500 2763
+1 62 825 80070
971 0503084105
Global Stem Cell Manufacturing Market Synopsis:The Global Stem Cell Manufacturing Market is growing with a CAGR of 10.1% in the forecast period of 2021 to 2028 and is expected to reach USD 23,505.08 million by 2028 from USD 11,076.78 million in 2020.The market dynamics study of an influential Stem Cell Manufacturing Market report demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead.
Important industry trends, market size, market share estimates are analysed and mentioned in the industry analysis report.
The large scale Stem Cell Manufacturing market report helps business in knowing its market share over various time periods, transportation, storage, and supply requirements of its products.Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market .Stem cells are body’s raw material which can differentiate into variety of cells.
The presence of large number of pipelines products along with strategic initiatives taken by market players are acting as opportunity for the market.
Lack of skilled professional may act as challenge for the market.Regional analysis, U.S. is dominating the global stem cell manufacturing in the North America region due to presence largest consumer market with high GDP, rise in chronic diseases and large number of players presence in the market.
Additionally, China is dominating the global stem cell manufacturing market in the APAC region due to increased awareness regarding the stem cell based treatment and advanced technology adoption.Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-stem-cell-manufacturing-market .Global Key Players:1 Thermo Fisher Scientific Inc2 Merck KGaA3 BD4 Organogenesis Inc5 Vericel Corporation6 ANTEROGEN.
